

SCIENTIFIC REPORTS



OPEN

Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder

Lucie Barateau^{1,2}, Isabelle Jausset², Régis Lopez^{1,2}, Elisa Evangelista^{1,2}, Sofiene Chenini¹, Meriem Benkiran³, Denis Mariano-Goulart^{3,4} & Yves Dauvilliers^{1,2}

The pathophysiology of rapid eye movement sleep behavior disorder (RBD) associated with narcolepsy type 1 (NT1) is still poorly understood, potentially distinct from idiopathic RBD (iRBD), but may share affected common pathways. We investigated whether MIBG cardiac uptake differs between iRBD and NT1 comorbid with RBD. Thirty-four patients with NT1-RBD and 15 patients with iRBD underwent MIBG cardiac scintigraphy. MIBG uptake was measured by calculating the early and delayed heart to mediastinum (H/M) ratios. A delayed H/M ratio lower than 1.46 was considered abnormal based on a population of 78 subjects without neurological or cardiac diseases. Patients with iRBD were older, had an older RBD onset age and higher REM sleep phasic and tonic muscular activities than NT1-RBD. Lower delayed and early H/M ratios were associated with iRBD, but not with NT1-RBD, in crude and adjusted associations. The delayed H/M ratio differed between iRBD and controls, after adjustment, but not between patients with NT1-RBD and controls. In conclusion, the MIBG cardiac uptake difference between NT1-RBD and iRBD supports the hypothesis of different processes involved in RBD pathogenesis, providing for the first time a cardiac biomarker to differentiate those disorders.

Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by repeated and often violent episodes of dream-enacting behaviors that may cause injury or sleep disruption^{1,2}. Preclinical and clinical evidences indicate that RBD results from the breakdown of the brainstem signaling network underlying REM sleep atonia, with an excess of muscle activity during REM sleep^{3,4}. RBD can be idiopathic (iRBD) or secondary. Secondary RBD can be associated with neurodegenerative disorders, especially synucleinopathies, narcolepsy, but also brainstem lesions, Guillain-Barré syndrome, intake of some drugs, and alcohol withdrawal². Conversely, iRBD is not associated with other neurological diseases, but often precedes the development of synucleinopathies.

The presence of RBD is frequently associated with autonomic dysfunction in both idiopathic and secondary form associated with Parkinson's disease (PD). Cardiac ¹²³I-labeled meta-iodobenzylguanidine (MIBG, a physiological norepinephrine analogue) scintigraphy is used to assess the function of postganglionic presynaptic cardiac sympathetic nerve endings. MIBG cardiac uptake is markedly decreased in patients with iRBD in the same range as in PD and dementia with Lewy bodies, and could be used as an early biomarker of iRBD^{5,6}. However, it is unclear whether and to which extent MIBG cardiac accumulation is impaired in the presence of secondary RBD outside the context of neurodegenerative diseases.

Narcolepsy type 1 (NT1) is a rare disease caused by the selective and irreversible loss of hypocretin neurons⁷. It is characterized by excessive daytime sleepiness (EDS), cataplexy, clinical manifestations related to REM sleep dysregulation (RBD, sleep paralysis and hypnagogic hallucinations) and frequent autonomic dysfunction^{7,8}. RBD is observed in up to 60% of patients with NT1, and may be the first symptom even in children^{9,10}. Differently from

¹National Reference Network for Narcolepsy, Sleep-Wake Disorders Center, Department of Neurology, Guide-Chauliac Hospital, Montpellier, Cedex 5, France. ²INSERM, University of Montpellier, Neuropsychiatry: Epidemiological and Clinical Research, Montpellier, France. ³Department of Nuclear Medicine, Montpellier University Hospital, Montpellier, Cedex 5, France. ⁴PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, Cedex 5, France. Correspondence and requests for materials should be addressed to Y.D. (email: y-dauvilliers@chu-montpellier.fr)

iRBD, RBD comorbid with NT1 does not show sex predominance (iRBD affects mostly men), movements are elementary rather than complex, behaviors are less violent, and RBD starts earlier¹¹.

The pathophysiology of RBD associated with NT1 is still poorly understood, highly probably distinct from that of iRBD, but may share affected common pathways in both conditions. Hypocretin deficiency could cause autonomic dysfunction, a functional defect in the motor control involved in the development of cataplexy during wakefulness and of RBD during sleep^{3,11}. However, recent studies showed that the brain functional connectivity during RBD episodes seems similar between patients with iRBD and RBD associated with NT1 or PD¹². Moreover, few studies reported the development of PD in patients with NT1^{13–16}, but the role of RBD in this association is unknown, and no study has assessed the frequency of synucleinopathies among patients with NT1. So far, it is not known whether RBD is a predictor for neurodegeneration in NT1.

Despite clear differences in phenotype between patients with iRBD and NT1 comorbid with RBD, we aimed in this study to investigate whether the ¹²³I-MIBG cardiac uptake profiles can differentiate patients with RBD whether idiopathic or symptomatic in the context of NT1.

Results

Compared with the NT1-RBD group, patients with iRBD were older, and also had older age of RBD onset, longer sleep-onset at night and REM sleep latency. Patients with iRBD displayed higher REM sleep phasic and tonic EMG activities. Specifically, 80% of them had tonic chin EMG density $\geq 30\%$ or phasic chin EMG density $\geq 15\%$, compared with 35.3% of patients with NT1-RBD (Table 1). Clinical RBD episodes were documented by vPSG recording in all patients with iRBD, but only in 57.1% of patients with NT1-RBD. Among iRBD patients, eight had an obstructive sleep apnea syndrome (OSAS): three severe OSAS (AHI ≥ 30 /h) and five moderate OSAS (AHI ≥ 15 and < 30 /h). All severe and one moderate OSAS patient were treated by continuous positive airway pressure (C-PAP) at time of scintigraphy. Among NT1 patients, eleven had OSAS (seven severe and four moderate OSAS), but only four patients were treated by C-PAP at time of scintigraphy, as this investigation was performed the day after PSG in most of NT1 patients.

Overall, 58.8% of the NT1 patients with RBD and 66.7% of the iRBD patients had a cardiovascular or metabolic comorbidity, without significant difference between the two groups (Table 1). Among iRBD patients, eight were treated with anti-hypertensive drugs (including two beta-blockers), and one with an antiarrhythmic drug at time of scintigraphy. Among NT1 patients, nine were treated with anti-hypertensive drugs (including two beta-blockers). Other patients were drug-free for cardiovascular or antihypertensive drugs at time of scintigraphy.

In crude and age-adjusted associations, lower cardiac MIBG uptake (i.e., lower delayed and early H/M ratios) was associated with iRBD, whereas the MIBG washout values were comparable in both groups (Table 2, Fig. 1). When the H/M ratio values were divided in tertiles, the lowest tertile (H/M ratio < 1.40) was associated with iRBD, but not with NT1-RBD, in crude and adjusted associations (Table 2).

In patients with iRBD, the delayed H/M ratio was not correlated with age, body mass index (BMI), RBD frequency, PLMS and AHI indexes, and REM sleep tonic and phasic EMG activities. The sensitivity analysis found no difference in the delayed H/M ratio in drug-free and treated (clonazepam) patients with iRBD ($n = 9$ vs $n = 6$).

In patients with NT1-RBD, the delayed H/M ratio was negatively correlated with age ($r = -0.48$; $p = 0.004$), BMI ($r = -0.53$; $p = 0.001$), and percentage of RSWA activity ($r = -0.4$; $p = 0.02$), but not with RBD frequency, phasic REM sleep EMG activities, PLMS and AHI indexes, and CSF hypocretin-1 levels. All associations, except for age, remained unchanged when the NT1-RBD subgroup of narcolepsy-drug-free patients at scintigraphy only ($n = 21$, 71% men, median age: 34 years, delayed H/M = 1.83 [1.46–2.29]) was analyzed. In addition, the delayed H/M ratio was higher in the drug-free ($n = 21$) than treated (psychostimulants and antiepileptic agents) NT1-RBD group ($n = 13$) ($p = 0.002$). However, this difference was not significant after adjustment for age.

In the control group ($n = 78$), the first decile of delayed H/M ratio was 1.46. Using this threshold to define abnormal values, thirteen (86.7%) patients with iRBD and four patients with NT1-RBD (11.8%) had pathological scintigraphy results. These four NT1-RBD patients with low H/M ratio (3 men and one woman, range 56–84 years old, BMI 26–48, delayed H/M 1.20–1.33, EMG phasic activity 5.5–27.5%, EMG tonic activity 1.9–94%) had a treatment for narcolepsy (psychostimulants and antiepileptic). Three of them had a cardiovascular comorbidity, three received antihypertensive drugs (but not beta-blockers), three had a non-dipping blood pressure profile, and two severe OSAS (including one using a CPAP at time of MIBG). None of these four patients had prodromal symptoms of Lewy body pathology: no subtle parkinsonian signs, no olfactory loss, and no constipation.

The delayed H/M ratio was significantly different between patients with iRBD and controls (H/M = 1.29 [1.03–1.68] vs 1.72 [1.22–2.65], $p < 0.0001$). This difference persisted after adjustment for age and sex ($p = 0.0007$). Conversely, the delayed H/M ratio was not different between patients with NT1-RBD and controls in crude and adjusted analyses (delayed H/M = 1.70 [1.20–2.29] vs 1.72 [1.22–2.65], $p = 0.82$).

Discussion

This study reports significant differences in cardiac ¹²³I-MIBG uptake between patients with iRBD and patients with NT1 and comorbid RBD. The threshold to define pathological cardiac MIBG values is challenging. Several cutoffs, from 1.4 to 2.8, were reported in the literature, with differences related to the involved populations, sample size, procedure and scanning methods (i.e., the used collimator), and statistical analyses¹⁷. Here, we defined the abnormal levels based on a control population of 78 subjects without neurological or cardiac disorders classified in quantiles, with low values below the lowest decile of 1.46 (local clinical normal values). We found that 87% of patients with iRBD, but only 12% of patients with NT1-RBD had abnormal H/M ratios. This supports the hypothesis of different pathophysiological processes between iRBD and NT1-associated RBD, an hypothesis that was predictable, but never proven, and consequently implies differences in the risk of conversion to neurodegenerative disorders.

Variable	NT1 with RBD N = 34		iRBD N = 15		p-value
	n	%	n	%	
Clinical characteristics					
Sex (Male)	25	73.53	12	80.00	0.73
Age at evaluation, years ^a	51.00 (15.00; 86.00)		72.00 (48.00; 82.00)		0.0002
BMI, kg/m ^{2a}	26.52 (17.00; 47.80)		25.40 (22.28; 33.80)		0.19
BMI, kg/m ² (≥ 30)	8	23.53	2	13.33	0.70
Cardiovascular and metabolic comorbidities ^b (yes)	20	58.82	10	66.67	0.60
Age of RBD onset, years ^a	36.00 (15.00; 65.00)		62.00 (47.00; 76.00)		<0.0001
RBD duration, years ^a	9.50 (0.50; 40.00)		6.00 (1.00; 15.00)		0.65
Daily RBD episodes (yes)	7	20.6	5	33.33	0.34
NT1 duration, years ^a	17.00 (0.50; 69.00)		—		
Nocturnal sleep characteristics					
Total Sleep Time, minutes ^a	369.50 (164.00; 522.00)		381.00 (229.00; 445.00)		0.81
Night Sleep Latency, minutes ^a	5.00 (0.00; 38.00)		31.00 (4.00; 106.00)		<0.0001
Night REM Sleep Latency, minutes ^a	55.00 (0.00; 328.00)		119.00 (35.00; 234.00)		0.03
Sleep efficiency, % ^a	77.81 (35.61; 95.55)		76.87 (50.90; 93.00)		0.65
% Stage 1 ^a	11.06 (2.52; 31.70)		7.99 (1.56; 16.25)		0.04
% Stage 2 ^a	47.68 (32.80; 78.05)		57.54 (32.89; 67.09)		0.17
% Stage 3 ^a	14.93 (0.00; 38.19)		12.04 (0.85; 38.99)		0.95
% REM sleep ^a	22.78 (1.81; 37.62)		20.05 (3.11; 30.89)		0.48
AHI /hour ^a	6.65 (0.00; 59.39)		10.21 (0.00; 37.77)		0.78
PLMS index, /hour ^a	8.52 (0.20; 161.89)		5.00 (0.00; 154.28)		0.47
Micro-arousal index, /hour ^a	21.95 (3.30; 68.57)		21.71 (2.23; 37.69)		0.92
Mean Oxygen Saturation % ^a	95.00 (87.00; 97.00)		94.00 (91.00; 96.00)		0.51
REM sleep without atonia					
Phasic EMG activity % ^a	9.15 (1.50; 31.67)		20.60 (2.86; 67.80)		0.006
Phasic EMG activity % ($\geq 15\%$)	9	26.47	12	80	0.002
Tonic EMG activity % ^a	19.15 (0.70; 96.43)		38.57 (1.25; 95.00)		0.02
Tonic EMG activity ($\geq 30\%$)	10	29.41	9	60	0.18
Phasic ($\geq 15\%$) or Tonic ($\geq 30\%$) EMG activities	12	35.29	12	80	0.01

Table 1. Clinical and polysomnographic characteristics of patients with narcolepsy type 1 (NT1) and rapid eye movement sleep behavior disorder (RBD), and of patients with idiopathic RBD (iRBD). ^aContinuous variables are expressed as median (minimal value; maximal value). REM = rapid eye movement, BMI = body mass index, AHI = apnea hypopnea index, PLMS = periodic leg movement during sleep, EMG = electromyography, MSLT = multiple sleep latency test, SOREMPs = sleep onset REM periods. ^bCardiovascular and metabolic comorbidities: Presence of diabetes type 2 or use of antidiabetic drugs, cardiac disorders (personal history of coronary artery disease, chronic heart failure, arrhythmia), hypertension or treatment with antihypertensive drugs, dyslipidemia or treatment with lipid-lowering drugs, or stroke.

Abnormal ¹²³I-MIBG cardiac scintigraphy results are currently considered as a strong biomarker of synucleinopathies¹⁸. Moreover, few studies showed cardiac sympathetic dysfunction even at early stages of iRBD^{5,6,19,20}. Specifically, compared with controls and also patients with multiple system atrophy or progressive supranuclear palsy, early and delayed H/M ratios are reduced in patients with iRBD to a similar extent as in patients with PD or dementia with Lewy bodies.

A study reported a correlation between iRBD duration and H/M ratio⁶. Similarly, in one of our patients with iRBD (onset age: 47 years), the delayed H/M ratio decreased over time (H/M = 1.35 at 62 years of age, at the time of study inclusion, 1.23 at 65 years, and 1.21 at 67 years). Other studies showed a more marked reduction of MIBG cardiac uptake in iRBD compared with early PD stages¹⁹, and also in PD with RBD compared with PD without RBD^{20,21}. These results suggest a more complex contribution of cardiac sympathetic dysfunction in the context of RBD. Postganglionic cardiac sympathetic denervation (i.e., loss of tyrosine hydroxylase-positive nerve fibers) is frequent in PD, and Lewy body (alpha-synuclein-positive) accumulation in the peripheral autonomic system precedes the neuronal loss in sympathetic ganglia²². In PD, decreased MIBG uptake reflects the cardiac sympathetic denervation and differences in MIBG accumulation depend on the injury level. Therefore, RBD could modify the extent of cardiac autonomic nerve denervation independently of motor symptoms. Accordingly, patients with iRBD often have orthostatic hypotension and cardiac dysfunction during wakefulness and sleep, with similar patterns observed in patients with PD and RBD compared with patients with PD without RBD^{20,21,23}. Moreover, cardiac autonomic dysfunction assessed by RR variability or MIBG may not predict the risk of neurodegenerative disease in patients with iRBD^{20,21,23}. Here, we found no correlation between the delayed H/M ratio and AHI indexes in both iRBD and NT1-RBD populations, as previously reported²⁴. The mechanism by which RBD is strongly associated with sympathetic alteration remains mostly unknown.

Variable	NT1 with RBD n = 34		iRBD n = 15		Model 0		Model 1	
	n	%	n	%	OR [95% CI]	p	OR [95% CI]	p
Delayed H/M ratio ^{a,b}	1.70 (1.20; 2.29)		1.29 (1.03; 1.68)		2.32 [1.42–3.80]	0.0008	2.07 [1.23–3.49]	0.006
Delayed H/M ratio								
<1.40 ^c	4	11.76	12	80.00	30.00 [5.82–154.63]	<0.0001	14.02 [2.31–85.03]	0.004
≥1.40	30	88.24	3	20.00	1		1	
Early H/M ratio ^{a,b}	1.64 (1.40; 2.29)		1.35 (1.08; 1.73)		3.05 [1.49–6.24]	0.002	2.44 [1.19–5.00]	0.02
MIBG washout % ^{a,d}	32.00 (24.00; 50.00)		38.00 (24.00; 56.00)		2.02 [0.85–4.79]	0.11	1.21 [0.46–3.19]	0.70

Table 2. Comparison of cardiac scintigraphy results in patients with narcolepsy type 1 (NT1) and rapid eye movement sleep behavior disorder (RBD) and in patients with idiopathic RBD (iRBD). ^aContinuous variables are expressed as median (minimal value; maximal value). ^bOR for 0.10-unit decrease. ^cLowest tertile of the sample vs the other two. ^dOR for 10-unit decrease. Model 0: crude association. Model 1: adjustment for age.




Figure 1. Delayed heart-to-mediastinum (H/M) ratio in patients with narcolepsy type 1 (NT1) with rapid eye movement sleep behavior disorder (RBD), in patients with idiopathic RBD (iRBD) and in controls. Results are shown as box-whisker plots with the median and 25th quartile of the delayed H/M ratio.

RBD was reported in 45 to 61% of patients with NT1¹¹, with recent findings showing its presence also in children even before sleepiness and cataplexy onset^{9,10}. The best RBD biomarkers are reduction of REM sleep atonia and excessive phasic REM sleep muscle activity. These parameters have been largely studied in iRBD and thresholds have been defined to differentiate patients and controls^{25–27}. However, no cut-off is currently available in the context of RBD associated with NT1^{28–30}. Here, we found increased REM sleep phasic and tonic EMG activities in patients with NT1-RBD, but to a lesser extent than in the iRBD group.

Pathophysiology of RBD whether idiopathic or symptomatic in the context of NT1 remains unclear, is often associated with autonomic dysfunction, and thus could have shared an alteration of common pathways under both conditions. Accordingly, recent ictal single-photon emission tomography studies explored the RBD pathways *in vivo* and showed similar activation in the bilateral premotor areas, interhemispheric cleft, periaqueductal area, dorsal and ventral pons and the anterior lobe of the cerebellum in patients with iRBD and in those with RBD associated with PD or NT1^{12,31,32}. Conversely, the significantly lower percentage of patients with NT1-RBD with abnormal MIBG H/M ratio (12% vs 87% in the iRBD group) in our study suggests a different pathophysiological origin. In NT1, cardiac tissue involvement has never been formally proved, although recent studies reported some alterations in sympathetic activities. Patients with NT1 have decreased resting muscle sympathetic nerve activity, heart rate, and blood pressure during wakefulness³³, and frequent non-dipper blood pressure profile associated with REM sleep dysregulation³⁴. Several preclinical and clinical evidences also support a direct effect of hypocretin on autonomic regulation³⁵. Hypocretin deficiency in NT1 could lead to dissociated REM sleep features, including REM sleep without atonia, increased density of phasic chin EMG during REM sleep, frequent shift from REM to non-REM sleep and wake, and could also trigger RBD³⁶. However, all patients with NT1 were hypocretin deficient but only half of them will develop RBD¹². In addition, the delayed MIBG H/M ratio did not correlate with CSF hypocretin-1 levels, but with the percentage of RSWA activity; a result in line with a recent study showing that CSF hypocretin-1 levels are normal in a small group of iRBD patients³⁷.

The association between NT1 and synucleinopathies remains controversial, with few available case-report studies^{13–16}, and RBD involvement in this association is unknown. As NT1 is an orphan disease, often starting in adolescent or young adults³⁸, it is difficult to conduct a prospective study in a large NT1 cohort to assess the incidence of synucleinopathies in the right age group. Based on our results, we plan to clinically follow very closely

the selected group of 4 NT1-RBD patients with abnormal MIBG scintigraphy, to assess on a potential development of synucleinopathies.

The present study has some limitations. The low sample size of patients with iRBD and NT1, the frequent cardiovascular and metabolic comorbidities and the frequent drugs intake for narcolepsy and cardiovascular disorders may theoretically influence MIBG results. However, the hypothetical effect of those medications would be to decrease H/M ratio, and thus increase the association between NT1-RBD and reduced MIBG accumulation, but we did not find such significant differences. Finally, as we included in this study only patients with RBD, a further MIBG scintigraphy study in a larger population of patients with NT1 with and without associated RBD compared to matched control subjects is required to evaluate the autonomic cardiac activity and identify patients with abnormal function.

To conclude, the MIBG cardiac uptake difference between patients with NT1-RBD and with iRBD supports the hypothesis of different processes involved in RBD pathogenesis, providing for the first time a cardiac biomarker to differentiate those disorders.

Methods

Participants. We included 34 patients with NT1 and comorbid RBD (NT1-RBD) (25 males, median age 51 years, range 15–86) at the Reference National Center for Narcolepsy of Montpellier, France. NT1 was diagnosed according to the ICSD-3 criteria¹: presence of EDS, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), at least two sleep-onset REM periods on MSLT or night polysomnography (PSG), cataplexy or low cerebrospinal fluid (CSF) hypocretin-1 levels (<110 pg/mL). CSF hypocretin-1 level was measured in 25 patients (74%) and was low in all of them. All patients were positive for HLA DQB1*06:02. RBD was defined according to the ICSD-3 criteria¹: history of injurious or disruptive sleep behaviors with dream enactment, documentation of their occurrence during REM sleep by video-PSG (vPSG), and demonstration of REM sleep without atonia (RSWA) by PSG.

Fifteen patients with a diagnosis of iRBD according to the ICSD-3 criteria¹ (12 males, median age 72 years, range 48–82) were also recruited. They all had a clinical history of dream-enactment behaviors and vPSG documentation of RBD.

Both groups of patients were carefully examined by a neurologist to exclude any association with neurological disorders (including extra-pyramidal symptoms and history of stroke).

The institutional review boards of the University of Montpellier-France approved this study. The methods were carried out in accordance with the approved guidelines. Each participant signed legal consent forms. Informed consent was obtained from all subjects.

A control clinical population recruited through the Medicine Nuclear Department of the University Hospital of Montpellier was included to determine the normal values for MIBG parameters, as threshold to define pathological cardiac MIBG values often differed in the literature, mainly due to the involved populations and procedure and scanning methods¹⁷. This group of 78 subjects (36 males, median age 53.5 years, range 10–84) had no neurological or cardiac disorders, no PSG assessment, and underwent ¹²³I-MIBG cardiac scintigraphy for another reason, mostly to exclude a pheochromocytoma.

Polysomnography. All patients underwent one-night vPSG recording in the sleep laboratory. Sleep stages were manually scored as well as micro-arousals, periodic limb movements during sleep (PLMS) and apnea-hypopnea index (AHI), according to standard criteria³⁹. REM sleep was scored without the chin electromyographic (EMG) criterion allowing for the maintenance of muscle tone during REM sleep. A 30-second-epoch of REM sleep was defined as tonic if tonic chin EMG activity was present for $\geq 50\%$ of the epoch. Phasic EMG activity was scored from the chin EMG recording and represented the percentage of 2-second mini-epochs of REM sleep containing phasic EMG events, defined as any burst of muscle activity lasting from 0.3 to 5 seconds with amplitude that exceeded four times the baseline EMG signal. RSWA was defined as the presence of a tonic REM activity that exceeded 30% of the total REM sleep duration, and phasic EMG activity was considered abnormal when higher than 15%²⁷.

Cardiac ¹²³I-MIBG scintigraphy. MIBG myocardial scintigraphy is a nuclear imaging technique that can evaluate the cardiac sympathetic function at a clinical level. It is a very sensitive measure of the post-ganglionic sympathetic activity of the myocardium. It provides useful information for evaluation of disease severity, prognosis, and therapeutic effects; in particular in patients with heart failure, ischemic heart diseases, or arrhythmic disorders. The heart to mediastinum ratio (H/M ratio) and the washout rate are the most common indices.

All patients underwent at rest myocardial sympathetic innervation scintigraphy using a General Electric INFINIA Hawkeye 4 gamma camera (GE Healthcare, Tirat Carmel, Israel) with low energy, high resolution collimators⁴⁰. Anterior planar 64 × 64 pixel images were acquired at 10 minutes (early phase) and 3 hours (delayed phase) after intravenous administration of ¹²³I-MIBG (185 MBq). Thyroid was blocked by oral administration of 130 mg of potassium iodine 1 hour before ¹²³I-MIBG injection⁴¹. The early and delayed (i.e., the most reliable MIBG biomarker) heart to mediastinum (H/M) uptake ratios were calculated by dividing the mean count in a manually-drawn, left ventricular region of interest (ROI) by the mean count in a 7 × 7-pixel ROI square placed in the upper mediastinum to avoid lung activity. The MIBG washout rate (i.e., the rate of MIBG washed out between the early and the delayed images) was calculated by comparing the cardiac count in the ventricular ROI of the early and delayed images⁴¹. The physicians who analyzed the scintigraphic data (DMG, MB) and calculated the delayed and early H/M ratios and MIBG washout rate were blinded to the diagnosis. Scintigraphy was performed after vPSG recording, with a median delay of 1 day (range 0–1830) for patients with NT1-RBD and 127 days (range 0–990) for patients with iRBD.

Cardiovascular and metabolic comorbidities, and treatment intake. Cardiovascular and metabolic comorbidities were defined as the presence of diabetes type 2 or use of antidiabetic drugs, cardiac disorders (personal history of coronary artery disease, chronic heart failure, arrhythmia), hypertension or treatment with antihypertensive drugs, dyslipidemia or treatment with lipid-lowering drugs, or stroke.

At the time of the scintigraphy, thirteen (38.2%) patients with NT1-RBD were taking drugs (psychostimulants: $n = 12$; antiepileptic agents: $n = 9$ (2 a selective serotonin-reuptake inhibitor (SSRI, fluoxetine), 5 a serotonin and norepinephrine reuptake inhibitor (SNRI, venlafaxine), and 2 a tricyclic antidepressant (clomipramine); sodium oxybate: $n = 2$); and six (40%) patients with iRBD were taking benzodiazepines (clonazepam) at low dose, and none antidepressants.

Statistical analysis. Categorical variables were presented as percentages, and quantitative variables as medians with ranges. Quantitative variables were mostly skewed according to the Shapiro-Wilk test. Demographic and clinical characteristics between patients with NT1-RBD and patients with iRBD were compared using the Chi-square or Fisher's exact test (for categorical variables) and the Mann-Whitney test (for continuous variables) (Table 1). To study the relationship between cardiac scintigraphy data and the two groups of patients, logistic regression models were used to estimate the odds-ratios (OR) and their 95% confidence interval (95% CI) (Table 2). Model 1 showed the non-adjusted association between cardiac scintigraphy variables and the two groups and model 2 the age-adjusted association. ORs evaluated the strength of the associations between cardiac scintigraphy variables and the two groups. Spearman's rank order correlations were used to determine associations between continuous variables (*i.e.* delayed ratio with continuous demographic and clinical characteristics such as age and BMI). The significance level was set at $p < 0.05$. Analyses were performed with the SAS software (version 9.4; SAS, Cary, NC).

References

1. AASM: American Academy of Sleep Medicine. *ICSD-3: International Classification of Sleep Disorders, 3rd ed.* American Academy of Sleep Medicine (2014).
2. Iranzo, A., Santamaria, J. & Tolosa, E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. *Lancet Neurol.* **15**, 405–419 (2016).
3. Luppi, P.-H. *et al.* The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. *Sleep Med. Rev.* **15**, 153–163 (2011).
4. Boeve, B. F. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. *Lancet Neurol.* **12**, 469–482 (2013).
5. Miyamoto, T. *et al.* Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. *Neurology* **67**, 2236–2238 (2006).
6. Miyamoto, T. *et al.* 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. *Sleep* **31**, 717–723 (2008).
7. Dauvilliers, Y., Arnulf, I. & Mignot, E. Narcolepsy with cataplexy. *Lancet* **369**, 499–511 (2007).
8. Scammell, T. E. Narcolepsy. *N. Engl. J. Med.* **373**, 2654–2662 (2015).
9. Nevsimalova, S., Prihodova, I., Kemlink, D., Lin, L. & Mignot, E. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. *Sleep Med.* **8**, 784–786 (2007).
10. Antelmi, E. *et al.* The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. *Brain J. Neurol.* **140**, 1669–1679 (2017).
11. Dauvilliers, Y., Jennum, P. & Plazzi, G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. *Sleep Med.* **14**, 775–781 (2013).
12. Mayer, G., Bitterlich, M., Kuwert, T., Ritt, P. & Stefan, H. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. *Brain J. Neurol.* **138**, 1263–1270 (2015).
13. Christine, C. W., Marks, W. J. & Ostrem, J. L. Development of Parkinson's disease in patients with Narcolepsy. *J. Neural Transm. Vienna Austria* **1996**(119), 697–699 (2012).
14. Economou, N.-T., Manconi, M., Ghika, J., Raimondi, M. & Bassetti, C. L. Development of Parkinson and Alzheimer diseases in two cases of narcolepsy-cataplexy. *Eur. Neurol.* **67**, 48–50 (2012).
15. Fialová, M., Dvořák, P., Dušek, P., Kovalská, P. & Sonka, K. Narcolepsy with cataplexy and Parkinson's disease. Case Report. *Neuro Endocrinol. Lett.* **36**, 226–230 (2015).
16. Mayer, G., Kesper, K., Oertel, W., Höffken, H. & Stiasny-Kolster, K. REM Sleep behavior disorder (RBD) in narcolepsy patients as a predictor of neurodegeneration: results of a prospective clinical and imaging investigation. *Sleep* **36**, vol. 36 Suppl pg. A236 (2013).
17. Yamashina, S. & Yamazaki, J. Neuronal imaging using SPECT. *Eur. J. Nucl. Med. Mol. Imaging* **34**, 939–950 (2007).
18. Orimo, S., Yogo, M., Nakamura, T., Suzuki, M. & Watanabe, H. (123I)-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α -synucleinopathies. *Ageing Res. Rev.* **30**, 122–133 (2016).
19. Kashiwara, K., Imamura, T. & Shinya, T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. *Parkinsonism Relat. Disord.* **16**, 252–255 (2010).
20. Nomura, T. *et al.* Relationship between (123I)-MIBG scintigrams and REM sleep behavior disorder in Parkinson's disease. *Parkinsonism Relat. Disord.* **16**, 683–685 (2010).
21. Miyamoto, T., Miyamoto, M., Iwanami, M. & Hirata, K. Cardiac 123I-MIBG accumulation in Parkinson's disease differs in association with REM sleep behavior disorder. *Parkinsonism Relat. Disord.* **17**, 219–220 (2011).
22. Orimo, S. *et al.* Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. *Acta Neuropathol. (Berl.)* **109**, 583–588 (2005).
23. Postuma, R. B., Gagnon, J. F., Vendette, M. & Montplaisir, J. Y. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. *Brain J. Neurol.* **132**, 3298–3307 (2009).
24. Miyamoto, T. *et al.* Comparison of severity of obstructive sleep apnea and degree of accumulation of cardiac 123I-MIBG radioactivity as a diagnostic marker for idiopathic REM sleep behavior disorder. *Sleep Med.* **10**, 577–580 (2009).
25. Ferri, R. *et al.* A quantitative statistical analysis of the submental muscle EMG amplitude during sleep in normal controls and patients with REM sleep behavior disorder. *J. Sleep Res.* **17**, 89–100 (2008).
26. Mayer, G. *et al.* Quantification of tonic and phasic muscle activity in REM sleep behavior disorder. *J. Clin. Neurophysiol. Off. Publ. Am. Electroencephalogr. Soc.* **25**, 48–55 (2008).
27. Montplaisir, J. *et al.* Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. *Mov. Disord. Off. J. Mov. Disord. Soc.* **25**, 2044–2051 (2010).
28. Dauvilliers, Y. *et al.* REM sleep characteristics in narcolepsy and REM sleep behavior disorder. *Sleep* **30**, 844–849 (2007).

29. Ferri, R. *et al.* Searching for a marker of REM sleep behavior disorder: submental muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. *Sleep* **31**, 1409–1417 (2008).
30. Knudsen, S., Gammeltoft, S. & Jennum, P. J. Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. *Brain J. Neurol.* **133**, 568–579 (2010).
31. Dauvilliers, Y. & Peigneux, P. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. *Brain J. Neurol.* **138**, e390 (2015).
32. Dauvilliers, Y. *et al.* Increased perfusion in supplementary motor area during a REM sleep behaviour episode. *Sleep Med.* **12**, 531–532 (2011).
33. Donadio, V. *et al.* Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy. *Neurology* **83**, 1080–1086 (2014).
34. Dauvilliers, Y. *et al.* Non-dipping blood pressure profile in narcolepsy with cataplexy. *PLoS One* **7**, e38977 (2012).
35. Plazzi, G. *et al.* Autonomic disturbances in narcolepsy. *Sleep Med. Rev.* **15**, 187–196 (2011).
36. Roth, T. *et al.* Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. *J. Sleep Res.*, <https://doi.org/10.1111/jsr.12468> (2016).
37. Anderson, K. N., Vincent, A., Smith, I. E. & Shneerson, J. M. Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder. *Eur. J. Neurol.* **17**, 1105–1107 (2010).
38. Dauvilliers, Y. *et al.* Age at onset of narcolepsy in two large populations of patients in France and Quebec. *Neurology* **57**, 2029–2033 (2001).
39. Iber, C., Ancoli-Israel, S., Chesson, A. & Quan, S. For the American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events; rules, terminology and technical specifications (2007).
40. Vauchot, F. *et al.* Assessment of the area at risk after acute myocardial infarction using 123I-MIBG SPECT: Comparison with the angiographic APPROACH-score. *J. Nucl. Cardiol. Off. Publ. Am. Soc. Nucl. Cardiol.* (2016).
41. Flotats, A. *et al.* Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. *Eur. J. Nucl. Med. Mol. Imaging* **37**, 1802–1812 (2010).

Author Contributions

Y.D. drafting/revising the manuscript for content, including medical writing for content; study concept or design; interpretation of data analysis, study supervision and coordination. L.B. writing the first draft of the manuscript/revising the manuscript for content, including medical writing for content; study concept or design; interpretation of data analysis; acquisition of data. I.J. drafting/revising the manuscript for content; study concept or design; statistical analysis and interpretation of data analysis. D.M.G. revising the manuscript for content; interpretation of data analysis; acquisition of data. R.L., E.E., S.C., M.B. acquisition of data and revising the manuscript for content.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018